Crestline Management LP Boosts Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Crestline Management LP lifted its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 31.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 200,857 shares of the company's stock after purchasing an additional 48,315 shares during the period. Crestline Management LP owned 0.25% of Viridian Therapeutics worth $3,850,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of the business. Cutter Capital Management LP lifted its holdings in shares of Viridian Therapeutics by 21.2% during the fourth quarter. Cutter Capital Management LP now owns 628,677 shares of the company's stock worth $12,052,000 after purchasing an additional 110,000 shares during the period. Braidwell LP acquired a new position in shares of Viridian Therapeutics during the fourth quarter valued at about $654,000. Brevan Howard Capital Management LP acquired a new stake in shares of Viridian Therapeutics in the 4th quarter worth about $258,000. Bayesian Capital Management LP raised its holdings in shares of Viridian Therapeutics by 99.2% in the 4th quarter. Bayesian Capital Management LP now owns 25,700 shares of the company's stock worth $493,000 after acquiring an additional 12,800 shares during the last quarter. Finally, Bank of America Corp DE raised its holdings in shares of Viridian Therapeutics by 36.5% in the 4th quarter. Bank of America Corp DE now owns 247,107 shares of the company's stock worth $4,737,000 after acquiring an additional 66,138 shares during the last quarter.

Wall Street Analyst Weigh In

Several research firms have commented on VRDN. HC Wainwright reiterated a "buy" rating and issued a $34.00 price objective on shares of Viridian Therapeutics in a research note on Wednesday, April 23rd. Royal Bank of Canada reduced their price objective on shares of Viridian Therapeutics from $46.00 to $45.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. Needham & Company LLC reduced their price target on shares of Viridian Therapeutics from $38.00 to $36.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. JMP Securities dropped their price objective on shares of Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating for the company in a report on Wednesday, May 7th. Finally, The Goldman Sachs Group lowered their price target on shares of Viridian Therapeutics from $31.00 to $27.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. One investment analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to data from MarketBeat, Viridian Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $36.70.

Viridian Therapeutics Trading Up 5.2%

VRDN stock traded up $0.65 during trading on Monday, reaching $13.04. The company had a trading volume of 312,100 shares, compared to its average volume of 1,193,708. Viridian Therapeutics, Inc. has a 52 week low of $9.90 and a 52 week high of $27.20. The company has a market cap of $1.06 billion, a P/E ratio of -3.03 and a beta of 0.57. The business has a 50 day moving average of $13.71 and a 200 day moving average of $17.44. The company has a debt-to-equity ratio of 0.04, a current ratio of 18.55 and a quick ratio of 18.55.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($0.87) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.95) by $0.08. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. The company had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.16 million. Viridian Therapeutics's revenue was up .0% on a year-over-year basis. As a group, sell-side analysts forecast that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current fiscal year.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.